balsalazide has been researched along with mesalamine in 83 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.61) | 18.7374 |
| 1990's | 17 (20.48) | 18.2507 |
| 2000's | 49 (59.04) | 29.6817 |
| 2010's | 12 (14.46) | 24.3611 |
| 2020's | 2 (2.41) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Giaffer, MH; Holdsworth, CD; O'Brien, CJ | 1 |
| Baron, JH; Barrison, IG; Giaffer, MH; Hoare, AM; Holdsworth, CD; Lennard-Jones, JE; Manjunatha, S; McIntyre, PB; Polson, RJ; Rodrigues, CA | 1 |
| Brown, P; Gibson, JA; Green, JR; Kerr, GD; Rowlinson, A; Swan, CH; Swarbrick, ET; Thornton, P | 1 |
| Baron, JH; Barrison, IG; Lennard-Jones, JE; McIntyre, PB; Rodrigues, CA; Thornton, PC; Walker, JG | 1 |
| Lennard-Jones, JE; McIntyre, PB | 1 |
| Baron, JH; Chan, RP; Gilbert, AP; Lennard-Jones, JE; Pope, DJ; Sacra, PJ | 1 |
| Kataoka, M; Kawasaki, M; Kimura, I; Nagahama, S; Sato, M | 1 |
| Kataoka, M; Kokuba, Y; Kumamoto, T; Matsuda, A | 1 |
| Gibson, JA; Green, JR; Hodgson, HJ; Holdsworth, CD; Kerr, GD; Leicester, RJ; Lobo, AJ; Parkins, KJ; Taylor, MD | 1 |
| Prakash, A; Spencer, CM | 1 |
| Gross, V | 1 |
| Kataoka, M; Kimura, I; Kokuba, Y; Kumamoto, T; Matsuda, A | 1 |
| Kataoka, M; Kawasaki, M; Kimura, I; Kokuba, Y; Matsuda, A; Nagahama, S | 1 |
| Crowe, JP; Gibson, JA; Green, JR; Holdsworth, CD; Kerr, GD; Lobo, AJ; Schofield, KJ; Swarbrick, ET; Taylor, MD | 1 |
| Kataoka, M; Kawasaki, M; Kimura, I; Kokurba, Y; Matsuda, A | 1 |
| Hanauer, SB | 3 |
| Blake, DR; Millar, AD; Rampton, DS; Simmonds, NJ | 1 |
| Regueiro, MD | 1 |
| Lowry, PW; Sandborn, WJ; Szumlanski, CL; Weinshilboum, RM | 1 |
| Green, JR | 1 |
| Adhiyaman, V; Froese, S; Vaishnavi, A | 2 |
| Johnson, LK; Kim, YS; MacGregor, DJ; Sleisenger, MH | 1 |
| Ragunath, K; Williams, JG | 1 |
| Franklin, CL; Lipsky, JJ; Loftus, EV; Lowry, PW; Mays, DC; Sandborn, WJ; Szumlanski, CL; Tremaine, WJ; Weaver, AL; Weinshilboum, RM | 1 |
| Brandes, JW; Ewald, U; Hämling, J; Howaldt, S; Koop, I; Krakamp, B; Kruis, W; Mönnikes, H; Pallant, D; Schreiber, S; Schütz, E; Stolte, M; Theuer, D | 1 |
| Gibson, JA; Green, JR; Kerr, GD; Mansfield, JC; Thornton, PC | 1 |
| Cann, PA; Giaffer, MH; Holdsworth, CD; Mansfield, JC; McKenna, D; Thornton, PC | 1 |
| Farrell, RJ; Peppercorn, MA | 1 |
| Bell, JK; Johnson, LK; Koval, G; Levine, DS; Pruitt, R; Riff, DS; Sales, D; Wruble, L | 1 |
| Goa, KL; Muijsers, RB | 1 |
| Hussar, DA | 1 |
| Schroeder, KW | 1 |
| Cross, A; Doty, P; Hanson, J; Hardi, R; Johanson, J; Johnson, LK; Koval, G; Pruitt, R; Riff, D; Safdi, M; Winston, B; Wruble, L | 1 |
| Green, JR; Johnson, LK; Pruitt, RE | 1 |
| Cohen, RD | 1 |
| Cummings, JH; Edmond, LM; Hopkins, MJ; Magee, EA | 1 |
| Biancone, L; De Nigris, F; Fantini, M; Fina, D; Geremia, A; Pallone, F; Tosti, C | 1 |
| Bjorkman, DJ; Kane, SV | 1 |
| Bjorkman, D; Kane, SV; Loftus, EV | 1 |
| Gibson, JA; Green, JR; Kerr, GD; Swan, CH; Swarbrick, ET; Thornton, PC | 1 |
| Buch, A; Hanauer, SB; Sandborn, WJ | 1 |
| Baker, DE; Kane, S | 1 |
| Brandimarte, G; Forti, G; Gigliobianco, A; Giorgetti, GM; Modeo, ME; Tursi, A | 1 |
| Chang, EB; Hanauer, SB; Kles, KA; Musch, MW; Turner, JR; Vavricka, SR | 1 |
| Bettenhausen, D; Jahraus, CD; Rubin, DT; Scherl, EJ | 1 |
| Bettenhausen, D; Jahraus, CD; Malik, U; Sellitti, M; St Clair, WH | 1 |
| Baker, DE | 1 |
| Sandborn, WJ | 1 |
| Choudhary, C; Cohn, JR; Kung, SJ; McGeady, SJ | 1 |
| Mackowiak, JI | 1 |
| Aguirre, A; Brass, C; Margarone, J; Markiewicz, M; Suresh, L | 1 |
| Aiello, F; Brandimarte, G; Elisei, W; Giorgetti, GM; Tursi, A | 1 |
| Assem, ES; Pearce, FL; Peh, KH; Wan, BC | 1 |
| Austin, D; Hogg, KJ; Jamieson, N; Robertson, E | 1 |
| Abdollahi, M; Nikfar, S; Rahimi, R; Rezaie, A | 1 |
| Tursi, A | 2 |
| Moss, AC; Patil, SA | 1 |
| Hu, J; Liu, XC; Mei, Q; Xu, JM | 2 |
| Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A | 1 |
| Attard, TM; Bortey, E; Forbes, WP; Heyman, MB; Pieniaszek, HJ; Pohl, JF; Quiros, JA; Walker, K | 1 |
| Rajapakse, R; Wiggins, JB | 1 |
| Gum, JR; Hayes, A; Johnson, LK; Kim, YS; McQuaid, KR; Sleisenger, MH; Terdiman, JP; Weinberg, VK | 1 |
| Abuhammad, A; Laurieri, N; Lowe, E; Ryan, A; Sim, E; Wang, CJ; Westwood, I | 1 |
| Candlish, W; Gravil, J; McGrane, J; Paravasthu, M | 1 |
| Laurieri, N; Ryan, A; Sim, E; Wang, CJ; Westwood, I | 1 |
| Rothenberg, ME; Sonu, I; Wong, R | 1 |
| Lee, CS; Lee, JJ; Mulberg, AE; Nelson, RM; Papadopoulos, EJ; Rodriguez, WJ; Sachs, HC; Sun, H | 1 |
| Coman, RM; Gjymishka, A; Glover, SC | 1 |
| Dhaneshwar, SS | 1 |
| Byeon, JS; Cho, EA; Chung, EJ; Do, EJ; Hwang, SW; Kim, JH; Kim, SY; Lee, HJ; Myung, SJ; Park, S; Park, SH; Ryu, YM; Yang, DH; Yang, SK; Ye, BD | 1 |
| Jeong, HJ; Kim, EM; Kim, IH; Kim, SH; Kim, SL; Kim, SW; Kim, YN; Lee, SO; Lee, ST; Liu, YC; Park, YR; Seo, SY | 1 |
| Kuriyama, A; Matsumura, M; Urushidani, S | 1 |
| Choi, YS; Kim, DS; Kim, JK; Kim, WJ; Lee, DH | 1 |
| Bracher, F; Dietschreit, JCB; Ghazy, E; Glas, C; Jung, M; Ochsenfeld, C; Sippl, W; Urban, L; Wössner, N | 1 |
| Damkier, P; Eisenberg, ML; Kjeldsen, J; Lindahl-Jacobsen, R; Streett, SE; Wensink, MJ | 1 |
20 review(s) available for balsalazide and mesalamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Balsalazide.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Drug Tolerance; Humans; Mesalamine; Phenylhydrazines | 1998 |
Review article: balsalazide therapy in ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines; Prodrugs | 2001 |
Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans; Mesalamine; Phenylhydrazines | 2002 |
Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Databases, Bibliographic; Female; Humans; Male; Mesalamine; Phenylhydrazines; Randomized Controlled Trials as Topic; Sex Factors; Treatment Outcome | 2002 |
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Humans; Mesalamine; Phenylhydrazines; Prodrugs; Sulfasalazine; Time Factors | 2002 |
Review article: maintenance treatment of Crohn's disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Crohn Disease; Gastrointestinal Agents; Humans; Immunosuppressive Agents; Mesalamine; Phenylhydrazines; Remission Induction; Secondary Prevention; Sulfasalazine; Tumor Necrosis Factor-alpha | 2003 |
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines; Treatment Outcome | 2003 |
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Phenylhydrazines; Randomized Controlled Trials as Topic | 2004 |
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Clinical Trials as Topic; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Labeling; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Product Surveillance, Postmarketing; Sensitivity and Specificity; Sulfasalazine | 2004 |
Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Clinical Trials as Topic; Humans; Inflammatory Bowel Diseases; Mesalamine; Phenylhydrazines; Safety | 2005 |
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Chemoprevention; Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Dose-Response Relationship, Drug; Humans; Mesalamine; Patient Compliance; Phenylhydrazines; Remission Induction; Sulfasalazine | 2006 |
Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Phenylhydrazines; Remission Induction | 2009 |
Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Diverticulitis, Colonic; Drug Therapy, Combination; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines; Probiotics; Prodrugs; Treatment Outcome | 2008 |
Balsalazide disodium for the treatment of ulcerative colitis.
Topics: Colitis, Ulcerative; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines | 2008 |
Balsalazide in treating colonic diseases.
Topics: Colitis, Ulcerative; Colonic Diseases; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines; Prodrugs; Treatment Outcome | 2009 |
Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines; Prodrugs; Remission Induction | 2009 |
Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fever; Humans; Male; Mesalamine; Pericarditis; Phenylhydrazines | 2014 |
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colon; Fatty Acids, Omega-3; Heparin, Low-Molecular-Weight; Humans; Inflammatory Bowel Diseases; Mesalamine; Phenylhydrazines; Prodrugs; Sulfasalazine | 2014 |
5-aminosalicylic acid agents for prevention of recurrent diverticulitis: A systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents; Databases, Bibliographic; Diverticulitis; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Randomized Controlled Trials as Topic; Recurrence; Secondary Prevention; Sulfasalazine; Treatment Outcome; Young Adult | 2018 |
20 trial(s) available for balsalazide and mesalamine
| Article | Year |
|---|---|
Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Sulfasalazine | 1992 |
Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Prospective Studies; Time Factors | 1992 |
Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Sulfasalazine | 1988 |
Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.
Topics: Aminosalicylic Acids; Animals; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Colitis, Ulcerative; Feces; Female; Humans; Male; Mesalamine; Mice; Mice, Inbred Strains; Phenylhydrazines; Rats; Rats, Inbred Strains; Time Factors | 1983 |
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Treatment Outcome | 1998 |
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Delayed-Action Preparations; Double-Blind Method; Female; Headache; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Secondary Prevention; Time Factors; Treatment Failure | 1998 |
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
Topics: Acute Disease; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Phenylhydrazines; Randomized Controlled Trials as Topic | 1999 |
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Mesalamine; Phenylhydrazines; Prodrugs | 2001 |
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Severity of Illness Index; Sigmoidoscopy; Sulfasalazine; Treatment Outcome | 2002 |
A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Female; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Severity of Illness Index; Sigmoidoscopy; Sulfasalazine; Treatment Outcome | 2002 |
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Blind Method; Female; Homeostasis; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Safety; Severity of Illness Index | 2002 |
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Child; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Middle Aged; Phenylhydrazines; Safety; Treatment Outcome | 2002 |
Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Cohort Studies; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle Aged; Patient Participation; Phenylhydrazines; Prognosis; Prospective Studies; Recurrence; Treatment Outcome | 2004 |
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cross-Over Studies; Female; Humans; Male; Mesalamine; Phenylhydrazines | 2004 |
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Probiotics | 2004 |
Prevention of acute radiation-induced proctosigmoiditis by balsalazide: a randomized, double-blind, placebo controlled trial in prostate cancer patients.
Topics: Acute Disease; Aged; Aminosalicylic Acids; Anti-Ulcer Agents; Colon, Sigmoid; Double-Blind Method; Humans; Male; Mesalamine; Phenylhydrazines; Pilot Projects; Proctocolitis; Prostatic Neoplasms; Radiation Injuries; Rectum | 2005 |
Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Diverticulitis, Colonic; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal Agents; Humans; Lacticaseibacillus casei; Male; Mesalamine; Middle Aged; Phenylhydrazines; Pilot Projects; Probiotics; Recurrence; Treatment Outcome | 2007 |
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Prospective Studies; Rectum; Severity of Illness Index; Sigmoidoscopy; Tablets; Treatment Outcome | 2009 |
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Topics: Adolescent; Aminosalicylic Acids; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Colon; Double-Blind Method; Female; Humans; Male; Mesalamine; Phenylhydrazines | 2009 |
Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study.
Topics: Adenoma; Aged; Apoptosis; Colon, Sigmoid; Colonic Neoplasms; Colonic Polyps; Double-Blind Method; Gastrointestinal Agents; Humans; Male; Mesalamine; Middle Aged; Phenylhydrazines; Prospective Studies | 2009 |
43 other study(ies) available for balsalazide and mesalamine
| Article | Year |
|---|---|
Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.
Topics: Aminosalicylic Acids; Drug Hypersensitivity; Female; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Phenylhydrazines; Sulfapyridine; Sulfasalazine | 1992 |
Reversal with balsalazide of infertility caused by sulphsalazine.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Infertility, Male; Male; Mesalamine; Phenylhydrazines; Sperm Count; Sulfasalazine | 1984 |
[Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats].
Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anthracenes; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Dextran Sulfate; Male; Mesalamine; Phenylhydrazines; Rats; Rats, Sprague-Dawley; Sulfapyridine; Sulfasalazine | 1997 |
Inhibition by aminosalicylates of lipid peroxidation in large intestinal mucosa after mesenteric ischemia/reperfusion in the rat.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Intestinal Mucosa; Intestine, Large; Lipid Peroxidation; Male; Mesalamine; Phenylhydrazines; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Splanchnic Circulation | 1997 |
Efficacy of different mesalamine-releasing drugs.
Topics: Acute Disease; Aminosalicylic Acids; Anti-Ulcer Agents; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines; Research Design | 1998 |
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Cytochrome c Group; Hydrogen Peroxide; Hypochlorous Acid; Kinetics; Mesalamine; Phenylhydrazines; Reactive Oxygen Species; Sulfapyridine; Sulfasalazine; Superoxides | 1998 |
Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Topics: Alanine; Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Interactions; Male; Mesalamine; Phenylhydrazines; Rats; Rats, Sprague-Dawley; Sulfapyridine; Sulfasalazine | 1998 |
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Topics: Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Chemotaxis, Leukocyte; Colitis, Ulcerative; Guinea Pigs; Humans; In Vitro Techniques; Male; Mesalamine; Neutrophils; Phenylhydrazines; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sulfapyridine; Sulfasalazine | 1998 |
Antioxidant effects of aminosalicylates and potential new drugs for inflammatory bowel disease: assessment in cell-free systems and inflamed human colorectal biopsies.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Ulcer Agents; Antioxidants; Cell-Free System; Colitis; Female; Humans; In Vitro Techniques; Inflammatory Bowel Diseases; Luminescent Measurements; Male; Mesalamine; Metronidazole; Middle Aged; Phenylhydrazines; Proctitis; Steroids | 1999 |
Will the real 5-aminosalicylic acid please stand up?
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines | 1999 |
Balsalazide and azathiprine or 6-mercaptopurine: evidence for a potentially serious drug interaction.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Antirheumatic Agents; Azathioprine; Drug Interactions; Drug Therapy, Combination; Humans; Inflammatory Bowel Diseases; Mercaptopurine; Mesalamine; Phenylhydrazines | 1999 |
Balsalazide and azathioprine or 6-mercaptopurine.
Topics: Administration, Oral; Aminosalicylic Acids; Antimetabolites; Azathioprine; Drug Interactions; Humans; Inhibitory Concentration 50; Mercaptopurine; Mesalamine; Methyltransferases; Phenylhydrazines; Prodrugs | 1999 |
Hypersensitivity reaction to balsalazide.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Drug Hypersensitivity; Female; Humans; Mesalamine; Middle Aged; Phenylhydrazines | 2000 |
Chemoprevention of colon cancer carcinogenesis by balsalazide: inhibition of azoxymethane-induced aberrant crypt formation in the rat colon and intestinal tumor formation in the B6-Min/+ mouse.
Topics: Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Anticarcinogenic Agents; Azoxymethane; Cell Division; Colonic Neoplasms; Genes, APC; Humans; Indomethacin; Intestinal Mucosa; Intestinal Neoplasms; Mesalamine; Mice; Mice, Mutant Strains; Phenylhydrazines; Prodrugs; Rats; Rats, Inbred F344; Tumor Cells, Cultured | 2000 |
Oral balsalazide (Colazal) for ulcerative colitis.
Topics: Abdominal Pain; Administration, Oral; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Hypersensitivity; Drug Interactions; Mesalamine; Nausea; Phenylhydrazines; Randomized Controlled Trials as Topic | 2001 |
Drug points: Hypersensitivity reaction to balsalazide.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Drug Hypersensitivity; Female; Humans; Mesalamine; Middle Aged; Pericarditis; Phenylhydrazines | 2001 |
Leucopenia resulting from a drug interaction between azathioprine or 6-mercaptopurine and mesalamine, sulphasalazine, or balsalazide.
Topics: Adult; Aminosalicylic Acids; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Binomial Distribution; Chromatography, High Pressure Liquid; Confidence Intervals; Drug Interactions; Female; Humans; Immunosuppressive Agents; Leukopenia; Male; Mercaptopurine; Mesalamine; Methyltransferases; Phenylhydrazines; Sulfasalazine; Thioguanine | 2001 |
Balsalazide disodium.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Drug Interactions; Female; Humans; Male; Mesalamine; Phenylhydrazines; Pregnancy | 2002 |
New drugs 2002, part 1.
Topics: Amides; Aminosalicylic Acids; Anti-Ulcer Agents; Antipsychotic Agents; Bimatoprost; Cloprostenol; Cyclohexanes; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Galantamine; Glaucoma; Gonadotropin-Releasing Hormone; Humans; Hypoglycemic Agents; Insulin; Insulin Glargine; Insulin, Long-Acting; Lipids; Mesalamine; Nateglinide; Nootropic Agents; Phenylalanine; Phenylhydrazines; Piperazines; Thiazoles; Travoprost | 2002 |
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as Topic; Colitis, Ulcerative; Data Interpretation, Statistical; Humans; Mesalamine; Phenylhydrazines | 2003 |
Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines | 2003 |
The mesalamine wars heat up-enter balsalazide.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans; Mesalamine; Phenylhydrazines; Randomized Controlled Trials as Topic | 2003 |
Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Humans; Mesalamine; Phenylhydrazines; United Kingdom; United States | 2003 |
The effect of 5-aminosalicylic acid-containing drugs on sulfide production by sulfate-reducing and amino acid-fermenting bacteria.
Topics: Amino Acids; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Desulfovibrio; Feces; Fermentation; Fusobacterium; Humans; In Vitro Techniques; Inflammatory Bowel Diseases; Mesalamine; Phenylhydrazines; Sulfasalazine; Sulfides | 2003 |
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Diarrhea; Disease Models, Animal; Gastrointestinal Agents; Ileum; Mesalamine; Phenylhydrazines; Prodrugs; Rabbits; Random Allocation; Sulfasalazine; Tissue Culture Techniques | 2005 |
Inflammation's role in rectal cancer following prostate radiotherapy, and emerging evidence for a protective role for balsalazide.
Topics: Aminosalicylic Acids; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Mesalamine; Neoplasms, Radiation-Induced; Phenylhydrazines; Primary Prevention; Prognosis; Prostatic Neoplasms; Radiation Injuries; Rectal Neoplasms; Risk Assessment; Treatment Outcome | 2005 |
Lack of cross-reactivity between 5-aminosalicylic acid-based drugs: a case report and review of the literature.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Crohn Disease; Cross Reactions; Drug Hypersensitivity; Exanthema; Herpes Simplex; Humans; Immunosuppressive Agents; Male; Mercaptopurine; Mesalamine; Phenylhydrazines; Prednisone | 2006 |
A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Decision Support Techniques; Humans; Mesalamine; Phenylhydrazines; Treatment Failure; United States | 2006 |
Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Gastrointestinal Agents; Humans; Male; Mesalamine; Phenylhydrazines; Stomatitis | 2007 |
Effect of sulphasalazine and balsalazide on histamine release from mast cells.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Gastrointestinal Agents; Histamine Release; Humans; Hydrogen Peroxide; Inflammatory Bowel Diseases; Mast Cells; Mesalamine; Oxidants; Phenylhydrazines; Rats; Sulfasalazine | 2007 |
Balsalazide-induced myocarditis.
Topics: Adult; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Male; Mesalamine; Myocarditis; Phenylhydrazines | 2008 |
[Effect of balsalazide on intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice].
Topics: Animals; Colitis; Dextran Sulfate; Female; Intestinal Mucosa; Male; Mesalamine; Mice; Mice, Inbred C57BL; Permeability; Phenylhydrazines | 2009 |
Balsalazine decreases intestinal mucosal permeability of dextran sulfate sodium-induced colitis in mice.
Topics: Animals; Colitis; Dextran Sulfate; Gastrointestinal Agents; Glutathione Peroxidase; Interferon-gamma; Intestinal Absorption; Intestinal Mucosa; Malondialdehyde; Mesalamine; Mice; Mice, Inbred C57BL; Peroxidase; Phenylhydrazines; Superoxide Dismutase; Tumor Necrosis Factor-alpha | 2009 |
Role of tyrosine 131 in the active site of paAzoR1, an azoreductase with specificity for the inflammatory bowel disease prodrug balsalazide.
Topics: Azo Compounds; Catalysis; Catalytic Domain; Crystallography, X-Ray; Enzyme Stability; Hot Temperature; Kinetics; Mesalamine; Mutagenesis, Site-Directed; NAD; NADH, NADPH Oxidoreductases; Nitroreductases; Phenylhydrazines; Protein Folding; Pseudomonas aeruginosa; Tyrosine | 2010 |
Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient.
Topics: Adult; Biopsy; Colitis, Ulcerative; Female; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines; Pulmonary Eosinophilia; Radiography, Thoracic; Tomography, X-Ray Computed | 2010 |
Reaction mechanism of azoreductases suggests convergent evolution with quinone oxidoreductases.
Topics: Benzoquinones; Catalytic Domain; Enzyme Stability; Evolution, Molecular; Flavins; Hot Temperature; Kinetics; Mesalamine; NAD; NADH, NADPH Oxidoreductases; NADP; Nitroreductases; Osmolar Concentration; Oxidation-Reduction; Phenylhydrazines; Phylogeny; Protein Binding; Pseudomonas aeruginosa; Spectrophotometry, Ultraviolet | 2010 |
5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Tamponade; Colitis, Ulcerative; Female; Humans; Mesalamine; Pericarditis; Phenylhydrazines; Sulfasalazine; Young Adult | 2013 |
Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.
Topics: Antibodies, Monoclonal; Colitis, Ulcerative; Humans; Infliximab; Mesalamine; Outcome Assessment, Health Care; Phenylhydrazines | 2014 |
Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Azoxymethane; bcl-2-Associated X Protein; Cell Transformation, Neoplastic; Colitis; Colon; Colorectal Neoplasms; Dextran Sulfate; Disease Models, Animal; Gastrointestinal Agents; Inflammation Mediators; Interleukin-6; Macrophages; Male; Mesalamine; Mice, Inbred C57BL; Phenylhydrazines; Phosphorylation; Probiotics; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; STAT3 Transcription Factor; Time Factors | 2016 |
Combined Parthenolide and Balsalazide Have Enhanced Antitumor Efficacy Through Blockade of NF-κB Activation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinogenesis; Cell Proliferation; Colitis; Colorectal Neoplasms; Drug Synergism; Female; Humans; Mesalamine; Mice; Mice, Inbred BALB C; NF-kappa B; Phenylhydrazines; Sesquiterpenes; Signal Transduction | 2017 |
Efficacy of topical 5-aminosalicylate monotherapy in patients with ulcerative proctitis with skip inflammation.
Topics: Administration, Ophthalmic; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Dermatitis; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Maintenance Chemotherapy; Male; Mesalamine; Middle Aged; Phenylhydrazines; Proctocolitis; Remission Induction; Treatment Outcome; Young Adult | 2018 |
Identification of the subtype-selective Sirt5 inhibitor balsalazide through systematic SAR analysis and rationalization via theoretical investigations.
Topics: Drug Design; Histone Deacetylase Inhibitors; Mesalamine; Molecular Docking Simulation; Phenylhydrazines; Protein Conformation; Salicylic Acid; Sirtuins; Structure-Activity Relationship | 2020 |
Balsalazide Exposure During the Development of Fertilizing Sperm May Be Associated With Offspring Birth Defects.
Topics: Congenital Abnormalities; Humans; Male; Mesalamine; Phenylhydrazines; Semen; Spermatozoa | 2022 |